TuHURA Biosciences Inc
tuhurabio.comWhat Do They Do?
Develops cancer immunotherapies for patients whose tumors resist other immunotherapies.
10-K for FY2025, filed Mar 31, 2026We are a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics…View ↗
Our proprietary Immune FxTM technology platform, or IFx, is an innate immune agonist technology designed to “trick” the body’s immune…View ↗
In addition to our IFx technology platform, in June 2025 we acquired the rights to TBS-2025, a novel VISTA-inhibiting monoclonal antibody…View ↗
In addition to our IFx and TBS-2025, we are leveraging our Delta Opioid Receptor (DOR) technology to develop first-in-class bi-functional…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 31, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$9.2MView ↗
- ▼ −3% (Loss)
- vs −$9.5M in Q2 FY2025
Treatment approach
The older report described a DNA-targeting chemotherapy candidate and a light-activated treatment; the latest centers on immune-based therapies, including an innate immune agonist, a VISTA-blocking antibody and antibody-drug conjugates targeting suppressor cells.
10-K for FY2022, filed Sep 27, 2022 10-K for FY2025, filed Mar 31, 2026Our two lead candidates are VAL-083, a novel, validated, DNA-targeting agent, for the treatment of drug-resistant solid tumors such as…View ↗
We are a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics…View ↗
Our proprietary Immune FxTM technology platform, or IFx, is an innate immune agonist technology designed to “trick” the body’s immune…View ↗
In addition to our IFx technology platform, in June 2025 we acquired the rights to TBS-2025, a novel VISTA-inhibiting monoclonal antibody…View ↗
In addition to our IFx and TBS-2025, we are leveraging our Delta Opioid Receptor (DOR) technology to develop first-in-class bi-functional…View ↗
Loading...
